KFDA approves new treatment option for late-stage breast cancer

The Korea Food and Drug Administration approved last Friday Halaven (eribulin mesylate) to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease.

Halaven was developed by Eisai Co., headquartered in Tokyo.

Halaven is a synthetic form of a chemotherapeutically active compound derived from the sea sponge Halichondria o...